Want to join the conversation?
Merck KGaA and $PFE said they launched two late-stage studies of drug avelumab in patients with ovarian and urothelial cancers. JAVELIN Ovarian 200 is a 550-subject, open-label, parallel group, global study, while JAVELIN Bladder 100 is a 668-subject global study.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?